Kpv 10mg Peptide For Sale

Sourcing High-Purity KPV 10mg for Laboratory Research

When sourcing a high-purity KPV 10mg research peptide for laboratory research, investigators require verified sequence identity, certified purity above 98%, and documented endotoxin testing. PX1 Research supplies USA-manufactured KPV in 10mg lyophilized vials, backed by lot-specific third-party certificates of analysis (COAs) utilizing RP-HPLC and mass spectrometry to ensure strict scientific reproducibility.

KPV is a tripeptide fragment corresponding to the C-terminal amino acid sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). In preclinical assays, this compact peptide has demonstrated potent anti-inflammatory properties without eliciting the pigmentary responses associated with full-length melanocortin agonist peptides. Sourcing verified research peptides allows laboratories to evaluate these signaling pathways with maximum control over confounders such as sequence degradation, trifluoroacetic acid (TFA) salt residues, or bacterial endotoxin contamination.

To maintain absolute integrity across experimental runs, PX1 Research packages KPV 10mg in sealed, vacuum-lyophilized glass vials designed for rapid reconstitution in aqueous buffers. Operating out of ISO 17025 accredited partner laboratories and cGMP-compliant manufacturing environments, PX1 ensures that every batch meets rigorous analytical parameters prior to dispatch from our California and Arizona logistics hubs.

Structural Characteristics & Molecular Identity of KPV Tripeptide

KPV is composed of three amino acid residues: L-Lysine, L-Proline, and L-Valine (Lys-Pro-Val). With a molecular formula of C16H30N4O4 and a exact monoisotopic mass of 342.23 g/mol, it represents one of the smallest bioactive peptide sequences derived from endogenous precursor proteins. Its primary structure preserves the functional core responsible for the non-pigmentary signaling effects observed in broader alpha-MSH derivative mechanisms.

The inclusion of the proline residue provides structural rigidity, stabilizing the peptide backbone against rapid enzymatic cleavage by non-specific aminopeptidases in cell culture media. The basic side chain of lysine combined with the hydrophobic valine terminus facilitates distinct electrostatic and hydrophobic interactions with cellular targets and transport proteins. In vitro binding studies indicate that KPV does not rely strictly on classic melanocortin receptors (MC1R–MC5R) to execute its biological signaling, setting it apart from broader melanocortin agonist peptides.

Mechanism of Action: NF-κB Pathway Modulation & Cytokine Downregulation

Preclinical investigations demonstrate that KPV acts primarily by modulating intracellular inflammatory cascades, most notably the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. In vitro assays using epithelial and immune cell lines indicate that KPV translocates across cell membranes—often mediated by the peptide transporter PepT1 (SLC15A1)—to directly inhibit the nuclear translocation of p65 and p50 NF-κB subunits.

By interfering with NF-κB activation, KPV effectively downregulates the transcription of pro-inflammatory cytokines, including interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and tumor necrosis factor-alpha (TNF-α). Furthermore, cellular assays demonstrate a reduction in inducible nitric oxide synthase (iNOS) expression, resulting in lowered cellular nitric oxide production under inflammatory challenge conditions. This intracellular mechanism allows KPV to temper hyper-inflammatory responses without triggering broad systemic immunosuppression.

Preclinical Literature: Intestinal Barrier Integrity and Epithelial Models

The primary body of literature surrounding KPV focuses on its efficacy in models of mucosal inflammation and intestinal epithelial disruption. In rodent models of experimental colitis—such as dextran sulfate sodium (DSS)-induced or trinitrobenzene sulfonic acid (TNBS)-induced colitis—administration of KPV resulted in significant reductions in histological inflammation scores, tissue myeloperoxidase (MPO) activity, and colon shortening.

In vitro models using Caco-2 monolayers demonstrate that KPV preserves epithelial tight junction architecture when challenged with inflammatory cytokines or pathogenic bacterial products. Researchers have observed upregulation and restored membrane localization of tight junction proteins, including Zonula Occludens-1 (ZO-1) and Occludin. These findings suggest that KPV plays a crucial role in maintaining mucosal barrier density, reducing paracellular permeability, and suppressing localized mucosal tissue destruction in specialized gut barrier peptide compounds.

Comparative Analysis: KPV vs. Complementary Anti-Inflammatory Compounds

In experimental biology, KPV is frequently evaluated alongside or in combination with other peptides that target cellular repair, tissue homeostasis, and mucosal protection. Comparing these mechanisms helps researchers design robust multi-target protocols:

While KPV targets intracellular NF-κB signaling and cytokine expression, compounds like BPC-157 10mg focus on promoting focal adhesion kinase (FAK) signaling, nitric oxide pathway modulation, and accelerated angiogenic responses. Conversely, antimicrobial research peptides such as LL-37 peptide operate via direct membrane disruption of pathogens and innate immune cell recruitment. For researchers analyzing tight junction reinforcement specifically, KPV is often contrasted with larazotide research models, which function as direct tight junction zonulin antagonists. Synthesizing data across these distinct classes offers a comprehensive view of mucosal defense systems.

Quality Verification: RP-HPLC, Mass Spectrometry, and Endotoxin Testing

To maintain rigorous research standards, PX1 Research imposes stringent quality control criteria on every batch of KPV 10mg. Synthetic peptides can harbor impurities such as truncated sequences, deletion peptides, or residual organic solvents if synthesis and purification processes are inadequately controlled.

Our quality assurance protocol requires twin analytical validations for every production lot: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm chemical purity (>98.0%), and Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-TOF MS) or ESI-MS to confirm precise molecular mass. Additionally, because KPV is frequently deployed in sensitive cell culture and animal tissue models, every batch undergoes Chromogenic Reagent Endotoxin Testing (LAL assay) to confirm endotoxin levels remain below strictly controlled laboratory thresholds (<0.01 EU/mg).

Laboratory Reconstitution and Reagent Handling Protocols

KPV 10mg is supplied as a sterile, lyophilized cake intended solely for laboratory reconstitution. Proper handling is critical to preserve peptide structure and prevent premature degradation:

Reconstitution should take place under a laminar flow hood using sterile laboratory solvents such as Bacteriostatic Water (0.9% benzyl alcohol), Sterile Normal Saline (0.9% NaCl), or phosphate-buffered saline (PBS, pH 7.4). Allow the lyophilized vial to equilibrate to room temperature before adding the diluent along the internal glass wall to avoid turbulent agitations. Gently swirl the vial until the powder is fully dissolved; avoid vigorous vortexing, which can introduce shear forces capable of destabilizing peptide secondary structures.

Storage Parameters and Stability Profile

Lyophilized KPV 10mg should be stored at -20°C for medium-term preservation or -80°C for extended archival storage, protected from direct light exposure. Under these conditions, the desiccated peptide cake maintains chemical stability for up to 24 months from the date of synthesis.

Once reconstituted into aqueous liquid solution, KPV should be kept refrigerated at 2°C to 8°C and utilized within 30 days if prepared with a preservative such as benzyl alcohol. For unpreserved aqueous solutions, liquid aliquots should be used immediately or snap-frozen at -80°C to prevent freeze-thaw cycles, which can degrade tripeptide bonds over time.

Procurement and Bulk Research Account Options

PX1 Research provides dependable procurement channels for university labs, private biotechnology firms, and institutional research facilities requiring consistent lot availability. Orders placed Monday through Friday before 3:00 PM EST ship same-day from our California and Arizona logistics centers.

For institutions conducting large-scale preclinical screening programs requiring high-volume peptide supplies, PX1 offers streamlined bulk research account options. Tiered institutional pricing, custom lot reservation, and automated documentation access ensure seamless integration into ongoing research workflows.